IR News
Mar. 02, 2022Print(PDF/139KB)Corporate
Sumitomo Dainippon Pharma Announces Changes in Executive Officers Including Representative Director, Organizational Realignment and Personnel Changes
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced the following organizational realignment and personnel changes of directors and executive officers, including representative director.
I. Change in Representative Director (effective March 31, 2022)
(1) Reason
Hitoshi Odagiri, Representative Director, Executive Vice President, offered to resign as the representative director as of March 31, 2022.
(2) Retiring Representative Director
| Name | New position | Current position | Hitoshi Odagiri | Member, Board of Directors | Representative Director, Executive Vice President |
|---|
II. Changes in Executive Officers
(1) Promotions (effective April 1, 2022)
Senior Executive Officer
Atsuko Higuchi (currently Executive Officer)
Takuya Taguchi (currently Executive Officer)
(2) New Executive Officers (effective April 1, 2022)
Naoki Noguchi (currently Chairman, President & CEO, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.)
Tsutomu Nakagawa (currently Senior Director, Global Corporate Strategy)
(3) Changes in the positions assumed by Executive Officers (effective April 1, 2022)
| Position as of April 1, 2022 | Current position | Name |
|---|---|---|
|
Representative Director, Executive Vice President Global Corporate Strategy; Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant |
Representative Director, Executive Vice President Chief Scientific Officer Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe Center; Regenerative & Cellular Medicine Manufacturing Plant |
Toru Kimura |
|
Member, Board of Directors, Senior Executive Officer Cancer Research; Modality Research; Drug Research Division Head of Japan Business Unit |
Member, Board of Directors, Senior Executive Officer Regulatory Affairs; Medical Information; Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Division; Technology Research & Development Division; Manufacturing Division Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Yoshiharu Ikeda |
| Member, Board of Directors |
Representative Director, Executive Vice President Sales & Marketing Division Executive Director, Sales & Marketing Division Senior Director, CNS Sales Department Head of Japan Business Unit |
Hitoshi Odagiri |
|
Senior Executive Officer Global Data Design Office; Legal Affairs; Intellectual Property; IT Management & Digital Transformation; Frontier Business Office |
Senior Executive Officer Global Data Design Office; External Affairs; Legal Affairs; Intellectual Property; Corporate Secretariat; IT Management & Digital Transformation; Frontier Business Office |
Hiroyuki Baba |
|
Senior Executive Officer Global Business Development; International Business Management |
Senior Executive Officer Global Corporate Strategy; Global Business Development; International Business Management |
Shigeyuki Nishinaka |
|
Senior Executive Officer Technology Research & Development Division; Manufacturing Division Deputy Head of Japan Business Unit |
Senior Executive Officer Drug Research Division Senior Executive Research Director, Drug Research Division |
Hideyuki Harada |
|
Senior Executive Officer External Affairs; Corporate Secretariat; Human Resources |
Executive Officer Corporate Governance; Corporate Communications; Human Resources |
Atsuko Higuchi |
|
Senior Executive Officer Sales & Marketing Division Executive Director, Sales & Marketing Division Deputy Head of Japan Business Unit |
Executive Officer Deputy Executive Director, Sales & Marketing Division |
Takuya Taguchi |
|
Executive Officer Regulatory Affairs; Medical Information; Medical Affairs; Corporate Regulatory Compliance & Quality Assurance Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Executive Officer Drug Development Division Executive Director, Drug Development Division Deputy Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Koichi Kozuki |
|
Executive Officer Senior Executive Research Director, Drug Research Division |
Executive Officer Executive Research Director, Drug Research Division |
Isao Shimizu |
|
Executive Officer Drug Development Division Executive Director, Drug Development Division Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc. |
Executive Officer Executive Vice President and Chief Corporate Strategy Officer, Sunovion Pharmaceuticals Inc. |
Yumi Sato |
|
Executive Officer Corporate Governance; Corporate Communications Senior Director, Corporate Governance |
Chairman, President & CEO, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. | Naoki Noguchi |
|
Executive Officer Senior Director, Global Corporate Strategy |
Senior Director, Global Corporate Strategy | Tsutomu Nakagawa |
|
Executive Officer CEO, Sumitomo Pharma Oncology, Inc. Global Head of Oncology |
Executive Officer CEO, Sumitomo Dainippon Pharma Oncology, Inc. Global Head of Oncology |
Patricia S. Andrews |
III. Organizational Realignment (effective April 1, 2022)
Corporate Departments
1. Oncology Strategy Unit is dissolved.
2. DSP Cancer Institute is renamed to Cancer Research Unit.
3. Modality Research Unit is created.
* Modality Research Unit is established for continuous development of drug discovery platforms based on diverse drug modalities, which leads to accelerate R&D process and improve R&D productivity and clinical success probability.
Sales & Marketing (Division)
1. Rare Diseases Office is created.
* We have signed a new alliance agreement with JCR Pharmaceuticals Co., Ltd. regarding the sales of recombinant Fabry disease therapeutic agents, and will start providing information to healthcare professionals from April 2022. Rare Diseases Office is established for ongoing contributions to the treatment of patients with Fabry disease.
2. Kobe Branch is integrated to Osaka Branch.
IV. Changes in Personnel (effective April 1, 2022)
Corporate Departments
| Position as of April 1, 2022 | Current position | Name |
|---|---|---|
| Senior Director, External Affairs | Director, External Affairs | Eiji Anzai |
| Senior Director, Human Resources | Senior Director, Corporate Governance | Masaki Yamamoto |
| Senior Director, Cancer Research Unit | Senior Director, DSP Cancer Institute | Setsuko Yamamoto |
|
Senior Director, Modality Research Unit Director, Group II, Modality Research Unit Senior Project Director, Drug Research |
Senior Fellow, Oncology Laboratory for Discovery Chemistry & Technology | Hitoshi Ban |
| Senior Officer, Vaccines | Senior Fellow, Vaccine Project, Drug Research | Akihisa Fukushima |
| Chairman, President & CEO, Sumitomo Pharma (Suzhou) Co., Ltd. |
Managing Director, Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. Managing Director, Sumitomo Pharma Malaysia Sdn. Bhd. |
Yoshitaka Koketsu |
|
Managing Director, Sumitomo Pharma Asia Pacific Pte. Ltd. Managing Director, Sumitomo Pharma Malaysia Sdn. Bhd. |
Member, Board of Directors, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. | Hiroki Uemukai |
Corporate Regulatory Compliance & Quality Assurance (Division)
| Position as of April 1, 2022 | Current position | Name |
|---|---|---|
| Senior Director, Regulatory Compliance & Quality Assurance Management | Senior Director, Technology Research & Development Management | Yuko Morioka |
Drug Research (Division)
| Position as of April 1, 2022 | Current position | Name |
|---|---|---|
| Executive Research Director, Drug Research Division | Senior Project Director, Late-phase Drug Research | Takeo Ishiyama |
| Senior Project Director, DMPK, Drug Research Division | Fellow, Preclinical Research Unit, DMPK | Takao Watanabe |
Technology Research & Development (Division)
| Position as of April 1, 2022 | Current position | Name |
|---|---|---|
| Senior Director, Technology Research & Development Management | Senior Director, Process Research & Development Laboratories | Mikio Sasaki |
| Senior Director, Process Research & Development Laboratories | Director, Medicinal Chemistry Group III, Chemistry Research Unit | Nobuhisa Fukuda |
Sales & Marketing (Division)
| Position as of April 1, 2022 | Current position | Name |
|---|---|---|
|
Deputy Executive Director, Sales & Marketing Division Senior Director, CNS Sales Department |
Senior Director, Osaka Branch | Ichiro Takahashi |
|
Deputy Executive Director, Sales & Marketing Division Senior Director, Tokyo Branch |
Senior Director, Human Resources | Koji Yamazaki |
| Senior Alliance Officer | Alliance Officer, Sales & Marketing Management | Hiroko Yuasa |
| Senior Director, Rare Diseases Office | Director, Product Group III, Product Marketing | Daisuke Ishigami |
| Senior Director, CNS Product Marketing | Psychiatry Area Marketing Officer, CNS Product Marketing | Masashi Kimura |
| Senior Director, Personnel Development | Senior Director, Kobe Branch | Tomoko Nakagawa |
| Senior Director, Sapporo Branch | Director, Human Resources Group, Human Resources | Toshinori Kanata |
| Senior Director, Tohoku Branch | Senior Director, Sapporo Branch | Katsuhiko Nishida |
| Senior Director, Kita-Kanto-Koshinetsu Branch | Senior Director, Personnel Development | Satsuki Otani |
| Senior Director, Keiji-Hokuriku Branch | Senior Director, Kita-Kanto-Koshinetsu Branch | Takafumi Shimizu |
| Senior Director, Osaka Branch | Senior Director, Kyushu Branch | Hidekatsu Kuroda |
| Senior Director, Kyushu Branch | Senior Director, Tohoku Branch | Manabu Tatsukawa |